Searched for
MANKIND PHARMA EARNINGS
Mankind Pharma shares key business developments from Q2 & H1 of FY27The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of...- Stocks in news: Infosys, Kotak Mahindra Bank, YES Bank, Raymond, BPCL, Coforge and Senco GoldIndian equity markets have faced a decline for four consecutive sessions, with the Nifty falling significantly. Various factors, including ...
- Stocks in news: RIL, Wipro, Jio Financial, Tata Communications, YES Bank, PNBFrom a technical perspective, the 23,000–23,100 zone remains an immediate resistance level for the Nifty, according to Ponmudi R, CEO of En...
- Ahead of Market: 10 things that will decide stock market action on WednesdayNifty’s indicative price plunged 2% in two seconds during the closing auction session on monthly expiry, before recovering sharply. Analyst...
- Ahead of Market: 10 things that will decide stock market action on TuesdayIndian equities gained on Monday as cooling oil prices and positive global cues lifted sentiment. Sensex rose 564 points to 74,859, while N...
- Mankind Pharma shares in focus after Q3 net profit drops 16% YoY to Rs 385 croreMankind Pharma's shares are in focus following a 16.5% YoY decline in Q3 net profit to Rs 385 crore, despite strong revenue growth of 24%. ...
- Mankind Pharma Q2 Results: Net profit rises 29% to Rs 659 crore, revenue up 13%Mankind Pharma witnessed a 29% surge in consolidated net profit, reaching Rs 658.88 crore in the second quarter, ending September 2024. Thi...
- Mankind Pharma Q1 Results: Profit rises 10% YoY to Rs 543 croreMankind Pharma Q1 Results: Revenue from operations for the same period increased by 12% year-on-year (YoY) to Rs 2,893 crore, up from Rs 2,...
- Mankind Pharma Q4 Results: Net profit jumps 62% YoY to Rs 477 croreMankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation...
- Mankind Pharma Q4 Results: PAT zooms 62% YoY to Rs 477 crore, revenue jumps 19%Mankind Pharma Q4 Results: The revenue from operations stood at Rs 2,441 crore versus Rs 2,053 crore reported in the year-ago period. Its b...
- Mankind Pharma Q3 Results: Net profit jumps 56% YoY to Rs 460 croreMankind Pharma on Wednesday reported a 56% year-on-year (YoY) jump in net profit to Rs 460 crore in Q3FY24 led by strong domestic formulati...
- Mankind Pharma Q3 Results: Cons PAT soars 60% YoY on robust all-round growthMankind Pharma Q3: Domestic revenue grew 20% YoY to Rs 2,400 crore, while exports more than doubled to Rs 207 crore. The strong domestic re...
- Mankind Pharma Q1 Results: PAT soars 66% YoY to Rs 487 crore on strong all-round showOperating profit, calculated as earnings before interest, taxes, depreciation and amortisation (EBITDA) for the quarter surged 43% YoY to R...
- Mankind Pharma Q4 Results: Net profit jumps 52% YoY to Rs 294 croreThe company reported net profit of Rs 193 crore during the corresponding period of the previous year. Revenue from Operations at Rs 2,053 c...
- Mankind Pharma Q4 Results: Cons PAT jumps 50% YoY to Rs 285 crore, sales up 19%For FY23, the company reported a 11% drop in consolidated net profit to Rs 1,282 crore, despite a 12.4% growth in revenue to Rs 8,749 crore.
- Mankind Pharma shares tank over 6% a day after solid debut. Time to buy?Shares of Mankind Pharma fell more than 6%, a day after its listing on the Indian stock exchanges at a premium. The company's IPO was the l...
- Mankind Pharma rallies 32% on day 1At Tuesday's closing price, Mankind Pharma was valued at a price-to-earnings ratio of 43 times its FY22 earnings. Mankind is now India's fi...
- Mankind Pharma shares list at 20% premium over IPO priceThe IPO, valued at Rs 4,326 crore, received an overwhelming response, being subscribed for 15.32 times due to interest from qualified insti...
- Mankind Pharma IPO: What GMP signals ahead of listing on TuesdayMankind Pharma is set to list on May 9 with a premium of Rs 120 apiece according to grey market trends. The company is valued at a price-to...
- Mankind Pharma may offer investors a better entry point after its listingBusiness: Unlike its peers, Mankind Pharma started in rural India and is now expanding to urban India. The company earns 97% of its revenue...
Load More
